ArticleNature communications2025
Recombinant expression systems for production of stabilised virus-like particles as next-generation polio vaccines.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Comparative immunogenic and structural analysis of virus-like particle and inactivated whole-virion vaccines against enterovirus D68.Molecular therapy. Nucleic acids · 2026Article
- Structural and functional mapping of protective human monoclonal antibodies against enterovirus A71.Science advances · 2026Article
- Article
- Engineering Viral Surface Antigens to Improve Display on Virus-like Particle (VLP) Vaccine Prototypes.Biotech (Basel (Switzerland)) · 2026Article
- Dynamic covalent polymer films formed by structural metamorphosis at nanoparticle surfaces.Polymer chemistry · 2026Article
- Review
- Structural insight into the assembly and D antigenicity of polio type 1 stabilized virus-like particles.NPJ vaccines · 2026Article
- The Use of Virus-like Particles as Immunogens to Treat Infectious Diseases.Current topics in medicinal chemistry · 2026Review
- Viral vector-driven trans-encapsidation of replicon RNAs as a rapid approach for the development of safe and economically attractive anti-enterovirus vaccines.bioRxiv : the preprint server for biology · 2025Article
- Characterization of a Sabin-like type 2/3 recombinant poliovirus with a triple nucleotide deletion in the VP1 region isolated from sewage.Virology journal · 2025Article
- Immune and Safety Analysis ofViruses · 2025Article
- Structural and stability differences among GI norovirus virus-like particles produced in silkworm-baculovirus expression vector system.Frontiers in microbiology · 2025Article
- Advances and challenges in poliomyelitis vaccines: a comprehensive review of development, production, and global deployment.Frontiers in public health · 2025Review
- MS2 virus-like particles as a versatile platform for multi-disease vaccines: a review.Frontiers in immunology · 2025Review
- Enteroviruses: epidemic potential, challenges and opportunities with vaccines.Journal of biomedical science · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
Polioviruses have caused crippling disease in humans for centuries, prior to the successful development of vaccines in the mid-1900's, which dramatically reduced disease prevalence. Continued use of these vaccines, however, threatens ultimate disease eradication and achievement of a polio-free world. Virus-like particles (VLPs) that lack a viral genome represent a safer potential vaccine, although they require particle stabilization. Using our previously established genetic techniques to stabilize the structural capsid proteins, we demonstrate production of poliovirus VLPs of all three serotypes, from four different recombinant expression systems. We compare the antigenicity, thermostability and immunogenicity of these stabilized VLPs against the current inactivated polio vaccine, demonstrating equivalent or superior immunogenicity in female Wistar rats. Structural analyses of these recombinant VLPs provide a rational understanding of the stabilizing mutations and the role of potential excipients. Collectively, we have established these poliovirus stabilized VLPs as viable next-generation vaccine candidates for the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.